Pub Date : 2024-03-01DOI: 10.1016/S0210-5705(24)00191-2
{"title":"ENDOSCOPIA (PÓSTERES)","authors":"","doi":"10.1016/S0210-5705(24)00191-2","DOIUrl":"https://doi.org/10.1016/S0210-5705(24)00191-2","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141241454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-27DOI: 10.1016/j.gastrohep.2024.02.001
Christian Navarro-Gerrard , Margalida Calafat , José Manuel Benítez , Cristina Suárez-Ferrer , Iria Bastón-Rey , Grupo Joven de GETECCU
{"title":"¿Son eficaces y seguros los fármacos biológicos en pacientes con EII y trasplante de órgano sólido?","authors":"Christian Navarro-Gerrard , Margalida Calafat , José Manuel Benítez , Cristina Suárez-Ferrer , Iria Bastón-Rey , Grupo Joven de GETECCU","doi":"10.1016/j.gastrohep.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.02.001","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139985841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-13DOI: 10.1016/j.gastrohep.2024.02.004
Douglas Maya-Miles , Javier Ampuero , David Martí-Aguado , Andrés Conthe , Rocío Gallego-Durán
{"title":"MASLD biomarkers: Are we facing a new era?","authors":"Douglas Maya-Miles , Javier Ampuero , David Martí-Aguado , Andrés Conthe , Rocío Gallego-Durán","doi":"10.1016/j.gastrohep.2024.02.004","DOIUrl":"10.1016/j.gastrohep.2024.02.004","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-13DOI: 10.1016/j.gastrohep.2024.02.003
Francisco Jorquera , Francisco Ledesma , Adriana Ahumada , María Luisa Manzano , Agustín Castiella , Sara Lorente , Mireia Miquel , Zoe Mariño , José Castellote , Eva Sanz , Juan Uriz
Background and aim of the study
There are still patients with hepatitis C in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve.
Methods
This sub-analysis describes the clinical profile of the 60 Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study.
Major results
Sixty percent of patients were male, median age 56 years, and 33% had a history of drug use. Almost three-quarters (71.3%) had more than one comorbidity and 78.3% took concomitant medication. At treatment initiation, median platelet count was 139 × 103/μL and FibroScan® 17 kPa. No virological failure was observed and no patient discontinued treatment due to adverse events. No clinically significant changes were noted during or after treatment in the median platelet, albumin, bilirubin, and transaminase levels.
Conclusions
Treatment with glecaprevir/pibrentasvir for 8 weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitis C among those patients still to be diagnosed and treated in Spain.
{"title":"Perfil clínico de los pacientes españoles con hepatitis C naïve con cirrosis compensada tratados en el estudio CREST","authors":"Francisco Jorquera , Francisco Ledesma , Adriana Ahumada , María Luisa Manzano , Agustín Castiella , Sara Lorente , Mireia Miquel , Zoe Mariño , José Castellote , Eva Sanz , Juan Uriz","doi":"10.1016/j.gastrohep.2024.02.003","DOIUrl":"10.1016/j.gastrohep.2024.02.003","url":null,"abstract":"<div><h3>Background and aim of the study</h3><p>There are still patients with hepatitis<!--> <!-->C in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve.</p></div><div><h3>Methods</h3><p>This sub-analysis describes the clinical profile of the 60<!--> <!-->Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study.</p></div><div><h3>Major results</h3><p>Sixty percent of patients were male, median age 56<!--> <!-->years, and 33% had a history of drug use. Almost three-quarters (71.3%) had more than one comorbidity and 78.3% took concomitant medication. At treatment initiation, median platelet count was 139<!--> <!-->×<!--> <!-->10<sup>3</sup>/μL and FibroScan® 17<!--> <!-->kPa. No virological failure was observed and no patient discontinued treatment due to adverse events. No clinically significant changes were noted during or after treatment in the median platelet, albumin, bilirubin, and transaminase levels.</p></div><div><h3>Conclusions</h3><p>Treatment with glecaprevir/pibrentasvir for 8<!--> <!-->weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitis<!--> <!-->C among those patients still to be diagnosed and treated in Spain.</p></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.1016/j.gastrohep.2024.02.002
Background
Acute lower gastrointestinal bleeding (ALGIB) is a common cause of hospitalization. Recent guidelines recommend the use of prognostic scales for risk stratification. However, it remains unclear whether risk scores are more accurate than some simpler prognostic variables.
Objective
To compare the predictive values of haemoglobin alone and the Oakland score for predicting outcomes in ALGIB patients.
Design
Single-centre, retrospective study at a University Hospital. Data were extracted from the hospital's clinical records. The Oakland score was calculated at admission. Study outcomes were defined according to the original article describing the Oakland score: safe discharge (the primary Oakland score outcome), transfusion, rebleeding, readmission, therapeutic intervention and death. Area under the receiver operating characteristics (AUROC) curve and accuracy using haemoglobin and the Oakland score were calculated for each outcome.
Results
Two hundred and fifty-eight patients were included. Eighty-four (32.6%) needed transfusion, 50 (19.4%) presented rebleeding, 31 (12.1%) required therapeutic intervention, 20 (7.8%) were readmitted and six (2.3%) died. There were no differences in the AUROC curve values for haemoglobin versus the Oakland score with regard to safe discharge (0.82 (0.77–0.88) vs 0.80 (0.74–0.86), respectively) or to therapeutic intervention and death. Haemoglobin was significantly better for predicting transfusion and rebleeding, and the Oakland score was significantly better for predicting readmission.
Conclusion
In our study, the Oakland score did not perform better than haemoglobin alone for predicting the outcome of patients with ALGIB. The usefulness of risk scores for predicting outcomes in clinical practice remains uncertain.
{"title":"Diagnostic accuracy of the Oakland score versus haemoglobin for predicting outcomes in lower gastrointestinal bleeding","authors":"","doi":"10.1016/j.gastrohep.2024.02.002","DOIUrl":"10.1016/j.gastrohep.2024.02.002","url":null,"abstract":"<div><h3>Background</h3><p>Acute lower gastrointestinal bleeding (ALGIB) is a common cause of hospitalization. Recent guidelines recommend the use of prognostic scales for risk stratification. However, it remains unclear whether risk scores are more accurate than some simpler prognostic variables.</p></div><div><h3>Objective</h3><p>To compare the predictive values of haemoglobin alone and the Oakland score for predicting outcomes in ALGIB patients.</p></div><div><h3>Design</h3><p>Single-centre, retrospective study at a University Hospital. Data were extracted from the hospital's clinical records. The Oakland score was calculated at admission. Study outcomes were defined according to the original article describing the Oakland score: safe discharge (the primary Oakland score outcome), transfusion, rebleeding, readmission, therapeutic intervention and death. Area under the receiver operating characteristics (AUROC) curve and accuracy using haemoglobin and the Oakland score were calculated for each outcome.</p></div><div><h3>Results</h3><p>Two hundred and fifty-eight patients were included. Eighty-four (32.6%) needed transfusion, 50 (19.4%) presented rebleeding, 31 (12.1%) required therapeutic intervention, 20 (7.8%) were readmitted and six (2.3%) died. There were no differences in the AUROC curve values for haemoglobin versus the Oakland score with regard to safe discharge (0.82 (0.77–0.88) vs 0.80 (0.74–0.86), respectively) or to therapeutic intervention and death. Haemoglobin was significantly better for predicting transfusion and rebleeding, and the Oakland score was significantly better for predicting readmission.</p></div><div><h3>Conclusion</h3><p>In our study, the Oakland score did not perform better than haemoglobin alone for predicting the outcome of patients with ALGIB. The usefulness of risk scores for predicting outcomes in clinical practice remains uncertain.</p></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-06DOI: 10.1016/j.gastrohep.2024.01.013
Felipe Silva , Miguel Bustamante , Gonzalo Latorre , Jorge Flandez , Isabella Montero , Eitan Dukes , Vicente Gandara , Camila Robles , Javier Uribe , Andrés Iglesias , Felipe Bellolio , María Elena Molina , Rodrigo Migueles , Gonzalo Urrejola , Tomás Larach , Nicolas Besser , Allan Sharp , Carlos Agüero , Arnoldo Riquelme , José Ignacio Vargas , Alberto Espino
Background
Small bowel tumors (SBT) are infrequent and represent a small proportion of digestive neoplasms. There is scarce information about SBT in Latin America.
Aim
To describe the epidemiology, clinical characteristics, diagnostic methods, and survival of malignant SBTs.
Methods
Retrospective observational study of adult patients with histopathological diagnosis of SBT between 2007 and 2021 in a university hospital in Chile.
Results
A total of 104 patients [51.9% men; mean age 57 years] with SBT. Histological type: neuroendocrine tumor (NET) (43.7%, n = 38), gastrointestinal stromal tumors (GIST) (21.8%, n = 19), lymphoma (17.2%, n = 15) and adenocarcinoma (AC) (11.5%, n = 10). GIST was more frequent in duodenum (50%; n = 12) and NET in the ileum (65.8%; n = 25). Metastasis was observed in 17 cases, most commonly from colon and melanoma. Nausea and vomiting were significantly more often observed in AC (p = 0.035), as well as gastrointestinal bleeding in GIST (p = 0.007). The most common diagnostic tools were CT and CT enteroclysis with an elevated diagnostic yield (86% and 94% respectively). The 5-year survival of GIST, NET, lymphoma and AC were 94.7% (95%CI: 68.1–99.2), 82.2% (95%CI: 57.6–93.3), 40.0% (95%CI: 16.5–82.8) and 25.9% (95%CI: 4.5–55.7%), respectively. NET (HR 6.1; 95%CI: 2.1–17.2) and GIST (HR 24.4; 95%CI: 3.0–19.8) were independently associated with higher survival compared to AC, adjusted for age and sex.
Conclusions
Malignant SBT are rare conditions and NETs are the most common histological subtype. Clinical presentation at diagnosis, location or complications may suggest a more probable diagnosis. GIST and NET are associated with better survival compared to other malignant subtypes.
背景：小肠肿瘤（SBT）并不常见，只占消化系统肿瘤的一小部分。目的：描述恶性小肠肿瘤的流行病学、临床特征、诊断方法和存活率：方法：对智利一所大学医院2007-2021年间组织病理学诊断为SBT的成年患者进行回顾性观察研究：共有104名SBT患者[51.9%为男性；平均年龄57岁]。组织学类型：神经内分泌瘤（NET）（43.7%，38 人）、胃肠道间质瘤（GIST）（21.8%，19 人）、淋巴瘤（17.2%，15 人）和腺癌（AC）（11.5%，10 人）。十二指肠腺癌（50%，12 人）和回肠母细胞瘤（65.8%，25 人）的发病率较高。17例患者出现转移，最常见的是结肠癌和黑色素瘤。恶心和呕吐明显多见于 AC（P=0.035），胃肠道出血多见于 GIST（P=0.007）。最常见的诊断工具是CT和CT肠溶解，诊断率较高（分别为86%和94%）。GIST、NET、淋巴瘤和AC的5年生存率分别为94.7%（95%CI：68.1-99.2）、82.2%（95%CI：57.6-93.3）、40.0%（95%CI：16.5-82.8）和25.9%（95%CI：4.5-55.7%）。经年龄和性别调整后，与 AC 相比，NET（HR 6.1；95%CI：2.1-17.2）和 GIST（HR 24.4；95%CI：3.0-19.8）与较高的生存率独立相关：恶性SBT是一种罕见病，NET是最常见的组织学亚型。诊断时的临床表现、位置或并发症可能提示更可能的诊断。与其他恶性亚型相比，GIST 和 NET 的生存率更高。
{"title":"Clinical features and prognosis of malignant small bowel tumors: Experience from a university hospital in Chile","authors":"Felipe Silva , Miguel Bustamante , Gonzalo Latorre , Jorge Flandez , Isabella Montero , Eitan Dukes , Vicente Gandara , Camila Robles , Javier Uribe , Andrés Iglesias , Felipe Bellolio , María Elena Molina , Rodrigo Migueles , Gonzalo Urrejola , Tomás Larach , Nicolas Besser , Allan Sharp , Carlos Agüero , Arnoldo Riquelme , José Ignacio Vargas , Alberto Espino","doi":"10.1016/j.gastrohep.2024.01.013","DOIUrl":"10.1016/j.gastrohep.2024.01.013","url":null,"abstract":"<div><h3>Background</h3><p>Small bowel tumors (SBT) are infrequent and represent a small proportion of digestive neoplasms. There is scarce information about SBT in Latin America.</p></div><div><h3>Aim</h3><p>To describe the epidemiology, clinical characteristics, diagnostic methods, and survival of malignant SBTs.</p></div><div><h3>Methods</h3><p>Retrospective observational study of adult patients with histopathological diagnosis of SBT between 2007 and 2021 in a university hospital in Chile.</p></div><div><h3>Results</h3><p>A total of 104 patients [51.9% men; mean age 57 years] with SBT. Histological type: neuroendocrine tumor (NET) (43.7%, <em>n</em> <!-->=<!--> <!-->38), gastrointestinal stromal tumors (GIST) (21.8%, <em>n</em> <!-->=<!--> <!-->19), lymphoma (17.2%, <em>n</em> <!-->=<!--> <!-->15) and adenocarcinoma (AC) (11.5%, <em>n</em> <!-->=<!--> <!-->10). GIST was more frequent in duodenum (50%; <em>n</em> <!-->=<!--> <!-->12) and NET in the ileum (65.8%; <em>n</em> <!-->=<!--> <!-->25). Metastasis was observed in 17 cases, most commonly from colon and melanoma. Nausea and vomiting were significantly more often observed in AC (<em>p</em> <!-->=<!--> <!-->0.035), as well as gastrointestinal bleeding in GIST (<em>p</em> <!-->=<!--> <!-->0.007). The most common diagnostic tools were CT and CT enteroclysis with an elevated diagnostic yield (86% and 94% respectively). The 5-year survival of GIST, NET, lymphoma and AC were 94.7% (95%CI: 68.1–99.2), 82.2% (95%CI: 57.6–93.3), 40.0% (95%CI: 16.5–82.8) and 25.9% (95%CI: 4.5–55.7%), respectively. NET (HR 6.1; 95%CI: 2.1–17.2) and GIST (HR 24.4; 95%CI: 3.0–19.8) were independently associated with higher survival compared to AC, adjusted for age and sex.</p></div><div><h3>Conclusions</h3><p>Malignant SBT are rare conditions and NETs are the most common histological subtype. Clinical presentation at diagnosis, location or complications may suggest a more probable diagnosis. GIST and NET are associated with better survival compared to other malignant subtypes.</p></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号